Drug Approval | December 12, 2023
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
